Cut to now, when both Wegovy and Zepbound have been removed from the shortage list
NEW YORK August 4, 2025 Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced the launch of the Noom Microdose GLP-1 Rx Program, a groundbreaking offering designed to unlock weight loss and long-term health benefits while minimizing side effects through personalized microdoses of GLP-1 medication, when clinically appropriate
This includes a complete metabolic panel, fasting insulin, HbA1c, fasting glucose, lipid panel (complete with LDL particle count if available), IGF-1, growth hormone levels (random and stimulated if possible), liver enzymes (ALT, AST, GGT), kidney function markers (creatinine, BUN, eGFR), complete blood count, and thyroid panel
The escalation in mechanism complexity heightens manufacturing cost but also raises efficacy and, by extension, value-based price ceilings
The key is finding the right combination for your specific needs and biology